Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.

ABSTRACT: In the last decade, different research groups in the academic setting have developed induced pluripotent stem cell-based protocols to generate three-dimensional, multicellular, neural organoids. Their use to model brain biology, early neural development, and human diseases has provided new insights into the pathophysiology of neuropsychiatric and neurological disorders, including microcephaly, autism, Parkinson's disease, and Alzheimer's disease. However, the adoption of organoid technology for large-scale drug screening in the industry has been hampered by challenges with reproducibility, scalability, and translatability to human disease. Potential technical solutions to expand their use in drug discovery pipelines include Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)

SUBMITTER: Costamagna G 

PROVIDER: S-EPMC7961877 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature